A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018, University of Michigan
Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Image created in 2014 by Tom Misteli, Ph.D., and Karen Meaburn, Ph.D. at the NIH IRP.

Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By looking at these systems, researchers at the University of Michigan Rogel Cancer Center have discovered that tumor reprogram metabolic pathways to gain control over a type of immune cell that allows growth.

Myeloid-derived suppressor cells live in the tumor microenvironment and work to block cancer immunity. They also encourage a stem cell-like growth that's linked to more aggressive cancer. Patients with a lot of these suppressor cells typically have worse outcomes. Essentially, their immune system isn't strong enough to fight against the tumor.

Further, when there are a large number of , immunotherapy treatments tend to be ineffective because the immune T-cells are suppressed.

By looking at cells, researchers found that the metabolic process by which cells break down glucose also regulates the expression of a specific isoform of C/EBP-beta that in turn causes more suppressor cells to develop. The immune system can't mount enough of an assault on the tumor cells, which translates to poor outcomes in triple-negative breast cancer .

"We don't have many treatment options for triple-negative breast cancer. One of the immunological reasons may be that these tumors have a large number of myeloid suppressor cells. This could be an issue. We hope that by understanding the biology better, it may lead to new ways to help these patients," says Weiping Zou, M.D., Ph.D., the Charles B. de Nancrede Professor of Surgery, Pathology, Immunology and Biology at the University of Michigan.

Essentially, it's a cascade: The process glycolysis initiates things. It targets a molecular mechanism called LAP, a specific isoform of C/EBP-beta, which then controls expression of G-CSF and GM-CSF, small proteins made by tumor cells, which support myeloid suppressor cells and result in immunosuppression.

Researchers examined this relationship in triple-negative breast cancer cell lines and in mouse models. They then looked at patient samples to assess how the metabolic pathway, the number of suppressor cells and immune signatures linked with patient survival. Looking at samples from 250 triple-negative breast cancer patients, they found that when the metabolic pathway for glycolysis was enriched, so were the immune suppressor cells—and this linked with worse overall survival. In contrast, tumors with a high T-cell signature exhibited fewer of these and the patients had better outcomes.

Explore further: For aggressive breast cancer in the brain, researchers clarify immune response

More information: Wei Li et al, Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer, Cell Metabolism (2018). DOI: 10.1016/j.cmet.2018.04.022

Related Stories

For aggressive breast cancer in the brain, researchers clarify immune response

April 17, 2018
Once it has begun to spread in the body, approximately half of patients with an aggressive breast cancer type will develop cancer in the brain. Researchers at the University of North Carolina Lineberger Comprehensive Cancer ...

Team targets tumor suppressor to treat 'triple-negative' breast cancer

February 5, 2018
A study by scientists at the University of Arizona Cancer Center and Cancer Research UK has found that the loss of a specific tumor suppressor in "triple-negative" breast cancer provides clues about potential new approaches ...

New key regulator of acquisition of immune tolerance to tumor cells in cancer patients

October 3, 2017
Researchers of the Chromatin and Disease Group from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona have identified a distinctive epigenetic event in immune cells that differentiate in the tumoral microenvironment ...

Researchers uncover how cancer stem cells drive triple-negative breast cancer

February 8, 2018
Cleveland Clinic researchers have published findings in Nature Communications on a new stem cell pathway that allows a highly aggressive form of breast cancer - triple-negative breast cancer - to thrive.

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Immune cells link pregnancy and tumor spread

June 6, 2011
Individuals with cancer often do not die as a result of their initial tumor but as a result of tumors at distant sites that are derived from the initial tumor. Pregnancy is a condition that seems to be permissive for tumor ...

Recommended for you

Sequencing genomes of Nigerian women could help prevent many lethal breast cancers

August 21, 2018
For the first time, DNA contributed by Sub-Saharan African women has been thoroughly evaluated with innovative genomics technology in an effort to understand the genetic bases for breast cancer in African populations.

Scientists take step toward new, targeted lung cancer treatment

August 21, 2018
Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications.

First in-depth profile of CAR T-cell signals suggests how to improve immunotherapy

August 21, 2018
CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling ...

Simple test could identify bladder cancer patients who won't respond to immunotherapy

August 21, 2018
Patients who are unlikely to benefit from a commonly used immunotherapy for bladder cancer could be identified by a simple blood test, according to researchers at Brighton and Sussex Medical School (BSMS).

New compound advances into Phase 1 trial for pancreatic cancer

August 21, 2018
A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively ...

Annual pap test a 'thing of the past?'

August 21, 2018
The United States Preventive Services Task Force (USPSTF) has released new recommendations on screening for cervical cancer. These latest recommendations continue the trend of decreasing participant burden by lengthening ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.